Immunome (NASDAQ:IMNM) Stock Price Down 5.7% – What’s Next?

Posted by Francis Steltz on Oct 13th, 2026

Immunome, Inc. (NASDAQ:IMNM – Get Free Report) dropped 5.7% during mid-day trading on Tuesday. The stock traded as low as $18.17 and last traded at $18.06. 163,892 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 1,352,647 shares. The stock had previously closed at $19.15.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Alliance Global Partners assumed coverage on shares of Immunome in a research note on Monday, September 21st. They issued a “buy” rating and a $32.00 target price for the company. Citigroup reiterated a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Wall Street Zen cut Immunome from a “sell” rating to a “strong sell” rating in a report on Sunday, October 4th. Truist Financial boosted their target price on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Wedbush increased their price objective on shares of Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.25.

Get Our Latest Analysis on Immunome

Immunome Trading Down 7.0%

The stock has a market capitalization of $2.02 billion, a P/E ratio of -7.05 and a beta of 2.55. The stock’s 50 day simple moving average is $24.94 and its 200 day simple moving average is $22.84.

Immunome (NASDAQ:IMNM – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.14). On average, sell-side analysts expect that Immunome, Inc. will post -2.51 EPS for the current fiscal year.

Insider Buying and Selling at Immunome

In related news, insider Jack Higgins sold 13,200 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $25.32, for a total value of $334,224.00. Following the completion of the transaction, the insider owned 65,050 shares in the company, valued at $1,647,066. This represents a 16.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 62,291 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $26.23, for a total transaction of $1,633,892.93. Following the completion of the transaction, the director owned 92,211 shares of the company’s stock, valued at $2,418,694.53. This trade represents a 40.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 223,368 shares of company stock valued at $5,747,142 in the last ninety days. Company insiders own 7.21% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several large investors have recently made changes to their positions in the business. Allworth Financial LP bought a new stake in Immunome during the second quarter worth approximately $25,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Immunome during the second quarter valued at approximately $27,000. Assetmark Inc. lifted its position in shares of Immunome by 46.6% in the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after acquiring an additional 1,442 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Immunome by 0.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 188,636 shares of the company’s stock valued at $3,997,000 after purchasing an additional 1,625 shares in the last quarter. Finally, KBC Group NV purchased a new stake in Immunome in the 1st quarter worth about $60,000. Institutional investors own 44.58% of the company’s stock.

About Immunome

(Get Free Report)

Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapeutics for cancer and immune-related diseases. The company uses its antibody discovery and development capabilities to identify potentially differentiated treatments designed to address significant unmet medical needs.

Immunome’s research activities are centered on building a pipeline of monoclonal antibody programs, including candidates directed at targets relevant to oncology and inflammatory or immune-mediated conditions.